Emerging Treatments and Future Outcomes

Lysosomal Storage Disorders: A Practical Guide

Volumn , Issue , 2012, Pages 174-180

  Andrew Burrow, T ^a   Grabowski, Gregory A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Blood brain barrier (BBB); Chinese hamster ovary (CHO) cells; Enzyme enhancement therapy (EET); Gene therapy; Induced pluripotent stem cells (iPSCs)

Indexed keywords

EID: 84886556897     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118514672.ch22     Document Type: Chapter

References (32)

1. Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010;285:20423-7.
2. Kirkegaard T, Roth AG, Petersen NH, Mahalka AK, Olsen OD, Moilanen I, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010;463:549-53.
3. Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 2004;83:163-74.
4. Lee WC, Tsoi YK, Troendle FJ, DeLucia MW, Ahmed Z, Dicky CA, et al. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J 2007;21:2520-7.
5. Savas PS, Hemsley KM, Hopwood JJ. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 2004;82:273-85.
6. Boado RJ, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 2008;99:475-84.
7. Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des 2008;14:1566-80.
8. Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng 2011;108:1954-64.
9. Xia H, Mao Q, Davidson BL. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001;19:640-4.
10. Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009;88:272-85.
11. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008;3:133-49.
12. Barrias CC, Lamghari M, Granja PL, Sa Miranda MC, Barbosa MA. Biological evaluation of calcium alginate microspheres as a vehicle for the localized delivery of a therapeutic enzyme. J Biomed Mater Res A 2005;74:545-52.
13. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011;12:316-28.
14. Cressant A, Desmaris N, Verot L, Brejot T, Froissart R, Vanier MT, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adenoassociated virus-mediated gene transfer in the striatum. J Neurosci 2004;24:10229-39.
15. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer J. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002;5:42-9.
16. Vite CH, McGowan JC, Niogi SN, Passini MA, Drobatz KJ, Haskins ME, et al. Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 2005;57(3):355-64.
17. Xia H, Anderson B, Mao Q, Davidson BL. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000;74:11359-66.
18. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19:463-74.
19. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212-5.
20. Rodriguez-Pascau L, Coll MJ, Vilageliu L, Grinberg D. Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease. Hum Mutat 2009;30 : E993-E1001.
21. Perez B, Rodriguez-Pascau L, Vilageliu L, Grinberg D, Ugarte M, Desviat LR. Present and future of antisense therapy for splicing modulation in inherited metabolic disease. J Inherit Metab Dis 2010;33:397-403.
22. Brooks DA, Muller VJ, Hopwood JJ. Stop-codon readthrough for patients affected by a lysosomal storage disorder. Trends Mol Med 2006;12:367-73.
23. Bunge S, Kleijer WJ, Steglich C, Beck M, Zuther C, Morris CP, et al. Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-l-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet 1994;3:861-6.
24. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-l-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001;10:291-9.
25. Angaji SA, Hedayati SS, Poor RH, Madani S, Poor SS, Panahi S. Application of RNA interference in treating human diseases. J Genet 2010;89:527-37.
26. Asano N, Ishii S, Kizu H, Ikeda K, Yasuda K, Kato A, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 2000;267:4179-86.
27. Steet RA, Chung S, Wustman B, Powe A, Do H, Kornfeld SA. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci USA 2006;103:13813-8.
28. Sun Y, Ran H, Liou B, Quinn B, Zamzow M, Zhang W, et al. Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse. PLoS One. 2011;6 : e19037.
29. Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Therond P, Scherman D. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab 2011;103:18-25.
30. Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis 2009;36:242-51.
31. Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007;110:2296-301.
32. Marshall J, McEachern KA, Chuang WL, Hutto E, Siegel CS, Shayman JA, et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 2010;33:281-9.